Privi Speciality Chemicals Q1FY26 profit rises 36%

Key Q1FY26 headline numbers

Privi Speciality Chemicals reported a sharp improvement in profitability for the quarter ended June 30, 2026 (Q1FY26), supported by stronger revenue from operations. Standalone net profit rose 22.7% year-on-year (YoY) to ₹84.26 crore. On a consolidated basis, net profit attributable to owners of the holding company increased 35.8% YoY to ₹84.21 crore.

The company also disclosed a strong rise in consolidated revenue and EBITDA for the quarter. Consolidated revenue was reported at ₹666 crore, up from ₹560 crore in the year-ago period, while EBITDA rose to ₹152 crore from ₹132 crore. The EBITDA margin narrowed slightly to 22.86% from 23.63% in the same quarter last year.

Standalone performance: profit up 22.7% YoY

On a standalone basis, Privi Speciality Chemicals said net profit increased 22.7% YoY to ₹84.26 crore for Q1FY26. The rise was attributed to higher revenue from operations.

The update also stated that standalone revenue from operations increased 6.0% YoY to ₹60.06 crore. (The same communication also carried larger consolidated revenue figures in rupee-billion terms, which translate to ₹ crore values shown later in this article.)

Consolidated performance: profit up 35.8% YoY

On the consolidated side, net profit attributable to owners climbed 35.8% YoY to ₹84.21 crore. Another disclosure in the same set of figures put consolidated net profit at ₹84.2 crore (₹842 million), up from ₹61.9 crore (₹619 million) in the year-ago period.

Consolidated revenue was reported at ₹666 crore (₹6.66 billion), compared with ₹560 crore (₹5.6 billion) a year earlier, implying a 19.2% YoY increase as cited by the company. The company also reported a 19.2% YoY surge in consolidated revenue from operations to ₹66.62 crore.

Operating segment: Aroma Chemical

The company said performance reflected strength in its single operating segment, Aroma Chemical. With only one disclosed segment, consolidated performance largely tracks the operating momentum of this business line.

Investors typically watch this segmentation closely because it clarifies whether growth is broad-based or concentrated. In Privi’s case, the disclosure indicates results are driven by the same core segment across standalone and consolidated reporting.

EBITDA growth, but margin slips

Alongside revenue growth, EBITDA increased to ₹152 crore from ₹132 crore in the year-ago quarter. However, the EBITDA margin eased to 22.86% from 23.63%.

This combination suggests operating profits rose in absolute terms, but costs grew at a pace that slightly outstripped revenue growth, leading to a small margin contraction. The company did not provide further detail on cost line items in the provided text, but the margin numbers capture the net effect.

Board approval and audit review

The Board of Directors approved the unaudited financial results at its meeting held on July 30, 2026. The company said this was pursuant to Regulation 30 read with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The results were reviewed by the statutory auditors, B S R & Co. LLP, which issued an unmodified limited review report. An unmodified report indicates the auditors did not flag material modifications in their limited review, based on the information cited.

Accounting note on March 31, 2026 quarter

The company also noted that figures for the quarter ended March 31, 2026 are balancing figures between audited full-year results and published nine-month figures. Such disclosures are common in quarterly reporting around the fiscal year-end because the fourth-quarter numbers can be derived as the difference between full-year audited results and previously reported nine-month figures.

Snapshot of reported financial metrics

The table below summarises the key figures specifically mentioned in the provided text, converted to a single unit of ₹ crore.

What this means for investors tracking Privi

For investors, the quarter stands out for two clear signals: profit growth outpaced revenue growth on a consolidated basis, and EBITDA increased in absolute terms. At the same time, the slight margin decline highlights that profitability expansion was not purely driven by operating leverage.

The presence of an unmodified limited review report and a clearly stated regulatory framework for the board-approved results adds procedural comfort for market participants who track governance and disclosure quality. With the company describing Aroma Chemical as its single operating segment, the market’s focus is likely to remain on demand and pricing dynamics within that core business.

Closing summary

Privi Speciality Chemicals delivered higher Q1FY26 profits on both standalone and consolidated bases, supported by improved revenues and higher EBITDA, even as margins dipped slightly. The company’s unaudited results were approved by the board on July 30, 2026 and were accompanied by an unmodified limited review report from B S R & Co. LLP.